Core Insights - Exousia Bio, Inc. has completed the acquisition of Exousia AI, Inc. in an all-stock transaction, issuing 62,223,000 restricted shares to consolidate ownership of a promising preclinical oncology platform [1] - The acquisition strengthens Exousia Bio's position in the exosome technology space, with two exclusive worldwide licenses secured for critical areas in cancer therapy and targeted drug delivery [2] - The company has received Orphan Drug Designation (ODD) from the FDA for its Glioblastoma therapy, marking a significant regulatory milestone [3][4] Financial and Strategic Advantages - The ODD provides substantial financial and strategic benefits, including an estimated potential value in the tens of millions of dollars [6] - The designation guarantees seven years of market exclusivity post-approval, offering a competitive advantage and protecting future revenue streams [10] - The company will benefit from tax credits for qualified clinical research costs and a waiver of New Drug Application user fees [10] Research and Development Progress - A completed in-vivo mouse study has shown extremely positive results for using exosomes to treat Glioblastoma multiforme, with findings being prepared for peer-reviewed publication [7] - To support the advancement of its pipeline, the company plans to expand its executive leadership and Board of Directors, including the appointment of a Chief Science Officer and Chief Medical Officer [8] Company Overview - Exousia Bio, Inc. specializes in developing and manufacturing mammalian and plant-derived exosomes using proprietary technologies for nucleic acid loading and targeted delivery [9] - The platform aims to address significant unmet medical needs, particularly in targeting cancer stem cells and treating a broad spectrum of viral infections [11]

Core Viewpoint - BrainStorm Cell Therapeutics Inc. has been granted an extension until June 30, 2025, by the Nasdaq Hearings Panel to regain compliance with certain continued listing standards of The Nasdaq Capital Market [1][2]. Group 1: Compliance and Listing - The company presented its compliance plan to the Nasdaq Hearings Panel on February 25, 2025, which resulted in the granted extension [2]. - The extension reflects the company's commitment to executing its compliance plan within the specified timeframe [2]. Group 2: Company Initiatives - The company is focused on launching a Phase 3b ALS study for its NurOwn® therapy, reducing overall debt, and pursuing strategic partnerships to enhance its pipeline [3]. - BrainStorm is dedicated to maintaining transparency and will provide updates as necessary during this process [3]. Group 3: Technology and Development - BrainStorm is a leading developer of therapies for neurodegenerative diseases, holding exclusive worldwide licensing rights for the NurOwn® technology platform, which produces autologous MSC-NTF cells [4]. - The NurOwn® cells have received Orphan Drug designation from the FDA and EMA for ALS, and the company is planning a confirmatory Phase 3b trial to evaluate safety and efficacy [4]. - The company has also completed a Phase 3 trial for NurOwn in ALS and is advancing studies in progressive multiple sclerosis, supported by grants from CIRM and NMSS [4].